Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
InventisBio Co., Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. This distribution indicates a fragmented prosecution landscape with multiple technical groups involved. Such a distribution suggests that the portfolio's current legal challenges are spread across multiple specialized domains rather than being concentrated in a single area.
MOORE, SUSANNA is the busiest examiner, though she is only handling 1 pending office action. With 3 distinct examiners each responsible for one action, no single examiner dominates the current workload. Practitioners must navigate the different requirements of 3 distinct art units to advance these applications. This requires a flexible strategy that can adapt to the specific requirements and examination styles of different technical divisions within the USPTO simultaneously.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011138 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | FETTEROLF, BRANDON J | 77d overdue |
| 18159688 | PD-L1 ANTIBODIES, FUSION PROTEINS, AND USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011138 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | FETTEROLF, BRANDON J | 77d overdue |
| 18515890 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | MOORE, SUSANNA | 4d overdue |
| 18159688 | PD-L1 ANTIBODIES, FUSION PROTEINS, AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1646 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18515890 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | MOORE, SUSANNA | 1624 | §103 | Non-Final OA | 4d overdue | Pending | Nov 21, 2023 |
| 18159688 | PD-L1 ANTIBODIES, FUSION PROTEINS, AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §102§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 18011138 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | FETTEROLF, BRANDON J | 1626 | §102§103 | Final Rejection | 77d overdue | Pending | Dec 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial